As I see it, my opinions.


The window of opportunity has now passed. Changing management at this point does nothing to help the average shareholder, their investment, the number of shares owned will soon be decimated in the wake of the reverse split that is about to take place.  


One can now only imagine what the scenario might have been if management had been thrown out long ago, a team put in place that had the interests of shareholders as their number one priority. A biotech firm that at one time had so much potential, a once thought of possible future player in the pain medication field is now reduced, as I see it, to a pitiful pathetic shell of a company.